Physician profile
Paul Michael Eckerle
NPI 1215317409
$18,323.13
in general payments reported to CMS, 2019-2025
23 companies · $7,328 in 2025
The $7,328 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2021: $370 · 2022: $3,090 · 2023: $3,297 · 2024: $4,027 · 2025: $7,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,802 · Education: $4,010 · Consulting Fee: $2,744 · Travel and Lodging: $2,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,801.52 |
| Education | $4,010.17 |
| Consulting Fee | $2,744.00 |
| Travel and Lodging | $2,097.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,332.52 | 2024-2025 | |
| Genzyme Corporation | $6,050.23 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,004.93 | 2021-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,550.04 | 2021-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $512.45 | 2022-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $476.25 | 2023-2025 | Dupixent |
| Grifols USA, LLC | $325.46 | 2023-2024 | Prolastin-C Liquid |
| Electromed, INC. | $253.32 | 2023-2025 | Smartvest |
| Genentech USA, INC. | $130.12 | 2019 | |
| Mylan Specialty L.P. | $125.79 | 2022-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $122.77 | 2024 | Winrevair |
| Philips North America LLC | $117.38 | 2022-2025 | Encore, (8874) Incourage |
| La Jolla Pharmaceutical Company | $79.47 | 2019 | |
| Baxter Healthcare | $50.69 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Boston Scientific Corporation | $32.01 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.78 | 2022 | |
| United Therapeutics Corporation | $23.36 | 2025 | Tyvaso |
| Paratek Pharmaceuticals, INC. | $21.19 | 2022 | |
| Optinose US, INC. | $21.16 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $20.23 | 2023 | Opsumit |
| Teva Pharmaceuticals USA, INC. | $18.34 | 2022 | |
| Viatris Specialty LLC | $17.02 | 2025 | Yupelri |
| Insmed, INC. | $14.62 | 2024 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Eckerle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.